805 related articles for article (PubMed ID: 29543938)
1. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.
Mulyadi R; Hasan I; Sidipratomo P; Putri PP
J Egypt Natl Canc Inst; 2024 May; 36(1):18. PubMed ID: 38797810
[TBL] [Abstract][Full Text] [Related]
3. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
[TBL] [Abstract][Full Text] [Related]
4. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.
Pinato DJ; D'Alessio A; Fulgenzi CAM; Schlaak AE; Celsa C; Killmer S; Blanco JM; Ward C; Stikas CV; Openshaw MR; Acuti N; Nteliopoulos G; Balcells C; Keun HC; Goldin RD; Ross PJ; Cortellini A; Thomas R; Young AM; Danckert N; Tait P; Marchesi JR; Bengsch B; Sharma R
Clin Cancer Res; 2024 Jun; 30(11):2433-2443. PubMed ID: 38578610
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.
Peng Z; Fan W; Liu Z; Xiao H; Wu J; Tang R; Tu J; Qiao L; Huang F; Xie W; Zhuang W; Guo W; Li S; Hua Y; Shen S; He Q; Li D; Li J; Kuang M
JAMA Surg; 2024 Apr; ():. PubMed ID: 38568599
[TBL] [Abstract][Full Text] [Related]
6. Brachytherapy with Iodine-125 seeds for treatment of portal vein-branch tumor thrombus in patients with hepatocellular carcinoma.
Hong D; Zhou Y; Wan X; Su H; Shao H
BMC Cancer; 2021 Sep; 21(1):1020. PubMed ID: 34521375
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial.
Choi JW; Kim HC; Han J; Jang MJ; Chung JW
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):372-378. PubMed ID: 38147153
[TBL] [Abstract][Full Text] [Related]
8. Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Parikh ND; Zhang P; Singal AG; Derstine BA; Krishnamurthy V; Barman P; Waljee AK; Su GL
Cancer Res Treat; 2018 Apr; 50(2):530-537. PubMed ID: 28602057
[TBL] [Abstract][Full Text] [Related]
9. Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma.
Vogl TJ; Nour-Eldin NE; Emad-Eldin S; Naguib NN; Trojan J; Ackermann H; Abdelaziz O
World J Gastroenterol; 2011 Mar; 17(10):1267-75. PubMed ID: 21455325
[TBL] [Abstract][Full Text] [Related]
10. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Li D; Zhang C; Yang K; Ma Z; Ma L; Cheng C; Xu L; Wan S
Medicine (Baltimore); 2024 Jan; 103(3):e36865. PubMed ID: 38241568
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study.
Li H; Wang J; Zhang G; Kuang D; Li Y; He X; Xing C; Wang Y; Shi M; Han X; Ren J; Duan X
Front Immunol; 2023; 14():1277329. PubMed ID: 38090566
[TBL] [Abstract][Full Text] [Related]
12. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
Wang X; Yang Y
Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study.
Bai T; Tang ZH; Wang XB; Chen J; Ye JZ; Lu SL; Wei M; Wu FX; Li LQ
Langenbecks Arch Surg; 2024 Mar; 409(1):97. PubMed ID: 38488934
[TBL] [Abstract][Full Text] [Related]
14. Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: The Effectiveness of Different Particle Sizes in Downstaging and Bridging in Living Donor Liver Transplantation.
Lim WX; Sim KS; Chen CL; Ou HY; Yu CY; Cheng YF
Transplant Proc; 2024 Apr; 56(3):596-601. PubMed ID: 38472083
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
Hou C; Xiong B; Zhou L; Fei Y; Shi C; Zhu X; Xie T; Wu Y
BMC Cancer; 2024 Mar; 24(1):387. PubMed ID: 38539150
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.
Wang K; Yu HM; Xiang YJ; Cheng YQ; Ni QZ; Guo WX; Shi J; Feng S; Zhai J; Cheng SQ
Future Oncol; 2022 Sep; 18(30):3367-3375. PubMed ID: 35968836
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma.
Hori A; Ohira R; Nakamura T; Kimura Y; Ueda S; Torii M; Kennoki N; Hori S
Br J Radiol; 2020 Jun; 93(1110):20190407. PubMed ID: 32142364
[TBL] [Abstract][Full Text] [Related]
19. Locoregional Therapies for Hepatocellular Carcinoma prior to Liver Transplant: Comparative Pathologic Necrosis, Radiologic Response, and Recurrence.
Mosenthal M; Adams W; Cotler S; Ding X; Borge M; Malamis A; Lee D; Thomas T; Jawahar A; Amin P; Molvar C
J Vasc Interv Radiol; 2024 Apr; 35(4):506-514. PubMed ID: 38123127
[TBL] [Abstract][Full Text] [Related]
20. Liver metastases of neuroendocrine tumors: Conventional transarterial chemoembolization and thermal ablation.
Vogl TJ; Gruber-Rouh T; Naguib NNN; Lingwal N; Bolik P
Rofo; 2024 Apr; 196(4):381-389. PubMed ID: 38109897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
